Neuralink Expands Brain Implant Trials with 12 Global Patients 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Asian Currencies Trade Sideways as Dollar Stabilizes, Yen Weakens Ahead of Japan Election 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Australia’s December Trade Surplus Expands but Falls Short of Expectations 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
